Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3…
Merus Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing…
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Associations 35th International Symposium on ALS/MND
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:…
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical…
NOTICE OF A GENERAL MEETING OF IBA SA
NOTICE OF A GENERAL MEETING OF IBA SA 7 January 2025 at…
IBA – Regulated Information
IBA SA – Information réglementée Le 6 décembre 2024,18:00 Publication effectuée en vertu…
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings…
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
A 30% reduction in long episodes was shown to be associated with…
Spineway provides an update on its activities during a webinar – Arrival of a new CFO
Press release Ecully, December 6, 2024 – 6 p.m. Spineway provides an…
Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day
BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards…